Michigan Breast Specialists-Grosse Pointe Woods

The trials here

What the 34 trials at this site are about, from their registry records.

Conditions

• Lung cancer10 trials
• Colorectal cancer5 trials
• Metastatic breast cancer4 trials
• Childhood cancers3 trials
• Prostate cancer3 trials
• Multiple myeloma2 trials
• Pancreatic cancer2 trials
• Triple-negative breast cancer2 trials
• Bladder cancer1 trial
• Cervical cancer1 trial
• Chronic myeloid leukaemia1 trial
• Glioblastoma1 trial
• and 3 more

Phase

• Phase 316 trials
• Phase 213 trials
• Phase 2/32 trials

Status

• Active, not recruiting22 trials
• Completed9 trials
• Suspended2 trials
• Terminated1 trial

Lead sponsor

• SWOG Cancer Research Network12 trials
• Alliance for Clinical Trials in Oncology10 trials
• ECOG-ACRIN Cancer Research Group8 trials
• GOG Foundation1 trial
• National Cancer Institute (NCI)1 trial
• and 2 more

Running trials

• Active, not recruiting

  Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

  NCT05633602· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

  NCT05241860· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

  NCT04637594· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

  NCT04455750· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

  NCT04597359· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

  NCT04462406· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

  NCT04533451· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

  NCT04233866· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

  NCT04137107· Phase 2/3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

  NCT04071457· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

  NCT03654768· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

  NCT03516942· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

  NCT02595424· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

  NCT00499330· Alliance for Clinical Trials in Oncology· Source

Closed trials

• Completed

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Terminated

  Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

  NCT03199885· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186· Phase 2· Wake Forest University Health Sciences· Source

• Completed

  Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

  NCT03633331· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· SWOG Cancer Research Network· Source

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451· Phase 3· GOG Foundation· Source

• Completed

  Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source